PharmaFocus Today – Page 310 – media

Prevalence of atopic diseases increased in sexually diverse individuals

The prevalence of atopic diseases, including atopic dermatitis, is increased in sexually diverse people, including those who identify as lesbian, gay, or bisexual, according to a research letter published online July 12 in JAMA Dermatology. Katelyn J. Rypka, from the University of Minnesota Medical School in Minneapolis, and colleagues calculated crude and multivariable-adjusted odd ratios for prevalence of atopic dermatitis, asthma, and allergic rhinitis comparing heterosexual and sexually diverse individuals. Data were included for 27,012 respondents to the 2021 National Health Interview Survey, of whom 25,701 were heterosexual and 1,311 were sexually diverse. The researchers found that sexually diverse individuals were more likely to report atopic dermatitis (11.1 versus 7.2 percent), asthma (12.0 versus 7.8 percent), and allergic rhinitis (33.7 versus 25.6 percent) compared with heterosexual individuals (adjusted odds ratios, 1.49, 1.39, and 1.30, respectively). In sex-stratified analyses, results were similar. “This study found higher rates of atopic disease among sexually diverse ...
- Source: drugdu
- 129
- July 15, 2023
Food insecurity tied to slightly faster memory decline

Food insecurity is associated with slightly faster memory decline in middle- to older-aged U.S. adults, according to a study published online July 3 in JAMA Network Open. Peiyi Lu, Ph.D., from Columbia University in New York City, and colleagues examined whether exposure to food insecurity is associated with changes in memory function among 12,609 middle- to older-aged U.S. adults (11,951 food-secure and 658 food-insecure) followed for 18 years (1998 to 2016). The researchers found that over time, the memory function of the food-secure respondents decreased by 0.045 standard deviation units annually (β for time, −0.045), with a faster memory decline rate among food-insecure respondents than food-secure respondents. However, the magnitude of the coefficient was small (β for food insecurity × time, −0.0030), yielding an estimated 0.67 additional (i.e., excess) years of memory aging over a 10-year period for food-insecure respondents compared with food-secure respondents. “The study noted a longitudinal association between food insecurity and memory ...
- Source: drugdu
- 170
- July 15, 2023
Roche’s New Subcutaneous Version Measures up to IV Ocrevus in Multiple Sclerosis

With the multiple sclerosis market growing rapidly—from $18.9 billion in 2020 to a projected $29.8 billion in 2030, according to GlobalData—Roche is primed to take advantage with Ocrevus (ocrelizumab).Now the monoclonal antibody, which racked (PDF) up nearly $7 billion in sales last year, appears on the verge of gaining an added advantage with a more convenient way to be administered. A phase 3 study has shown that a new, subcutaneous version of Ocrevus has proven to be non-inferior to the current infused treatment as measured by the level of drug in the blood, 12 weeks after administration. Specific numbers were not included in Roche’s release but the company said that the trial achieved both its primary and secondary endpoints. The injected version also matched the performance of the infused treatment in controlling magnetic resonance imaging (MRI) lesion activity in the brain over 12 weeks, Roche said. The injected regimen of Ocrevus is a ...
- Source: drugdu
- 171
- July 15, 2023
2023 Mid-Year Review

BTIG analysts share insights gleaned from tracking medical device clearances, approvals, and FDA review times. COVID-related backlog at FDA had a real impact on medtech approvals there for a while. Now that the pandemic is officially over, are things back to normal for medical device approvals? Medtech analysts at BTIG recently shared some mid-year insights based on multiple years of tracking FDA approval databases. The bottom line: 510(k) clearances are down a bit, PMA approvals are on track to grow substantially, and review times have been mixed depending on the pathway. Through June, there were 1,586 510(k) clearances. At this pace, there would be about 3,075 FDA clearances at the end of the year, representing a 4.4% dip compared to the number of clearances in 2022. The analysts at BTIG noted that it is taking an average of 162.8 days for the agency to render a decision regarding a 510(k) ...
- Source: drugdu
- 202
- July 15, 2023
Urotronic Wins FDA Approval to challenge Boston Scientific, Teleflex for Prostate Market

Dive Brief The U.S. Food and Drug Administration has approved Urotronic’s minimally invasive surgical treatment of symptoms linked to benign prostatic hyperplasia (BPH), the company announced Tuesday. BPH is defined by the expansion of the prostate. As the organ grows, it can cause changes in the bladder that result in lower urinary tract symptoms such as leaking urine. Urotronic’s newly approved Optilume BPH catheter system is designed to tackle the symptoms through mechanical dilation and the delivery of paclitaxel to stop the problem from recurring. Dive Insight Researchers studied the use of balloon dilation in BPH in the 1990s, but the technique failed to provide long-term benefits. Urotronic has tried to address that problem by pairing the immediate symptomatic relief provided by balloon dilation with localized delivery of paclitaxel, a drug that is already widely used in cardiovascular devices to prevent blood vessels from narrowing after ...
- Source: drugdu
- 122
- July 15, 2023
Macrophages May Play a Major Role in the Development of Atrial Fibrillation

Current treatments for atrial fibrillation (AFib), a common heart condition characterized by fast and irregular beats that can lead to stroke and heart failure, have multiple side effects and are ineffective for preventing AFib recurrence. New research led by investigators at Massachusetts General Hospital (MGH) and published in Science reveals that certain immune cells play a major role in the development of AFib. Targeting these cells may therefore represent a promising strategy to treat and prevent AFib. For the work, senior author Matthias Nahrendorf, MD, PhD, an investigator in MGH’s Center for Systems Biology and the Richard Moerschner Endowed MGH Research Institute Chair in Men’s Health, and colleagues analyzed single cells from atrial heart tissue collected from patients with and without AFib. The analyses indicated that immune cells called macrophages are the most dynamic cell population in the atria during AFib, and these cells expand more than any ...
- Source: drugdu
- 97
- July 15, 2023
Can CorWave Fill Medtronic’s Shoes in the LVAD Market?

Medtronic’s exit from the left ventricular assist device (LVAD) market left a huge void. A small French company wants to fill it. A small French company has some mighty big shoes to fill in the left ventricular assist device (LVAD) market. When Medtronic pulled the plug on its embattled HeartWare ventricular assist device in 2021, the departure created a significant void in the LVAD market and highlighted the urgent need for innovation in the space to improve outcomes for end-stage heart failure patients. Abbott said it had the capacity and supply to effectively support the growing demand for mechanical circulatory support devices with its HeartMate 3 device, but Abbott and other LVAD makers suffer from limitations of using rotary pump technology, according to CorWave CEO Louis de Lillers. Clichy, France-based CorWave is developing an implantable heart pump for advanced heart failure patients that is based on a technology called ...
- Source: drugdu
- 102
- July 15, 2023
Eisai, Biogen’s Leqembi May Face Rollout Hurdles Now, but Experts Still Like the Alzheimer’s Drug

After a full FDA approval last week triggered Medicare coverage of Eisai and Biogen’s Leqembi, doctors are still trying to work out the logistics of testing and reimbursement. But at least two experts remain positive about the drug’s efficacy and safety profile.The new Leqembi label carries a boxed warning about the risks of brain bleeding and swelling known as amyloid-related imaging abnormalities (ARIA). But two Alzheimer’s opinion leaders suggested the side effect is manageable typically by extensive monitoring in the first six months, Leerink Partners analysts said in a Wednesday note. But the two experts were split on whether they intend to treat patients with the ApoE ε4 genetic trait. The FDA label requires testing for that biomarker before initiating Leqembi to inform the risk of ARIA. While one expert felt comfortable giving Leqembi to APOE4 carriers as long as the patients are informed of the risk, the other ...
- Source: drugdu
- 103
- July 15, 2023
Racial Discrimination Increases Risk for Childhood Obesity

Children who experience racial discrimination are more likely to later have a higher body mass index (BMI) and larger waistline, according to a new study published in JAMA Network Open. The findings illustrate that racial discrimination may be a risk factor for young people developing obesity—above and beyond other socioeconomic factors such as family income. “Exposure to racial discrimination must be acknowledged as both a social determinant of obesity and a significant contributor to obesity disparities among children and adolescents,” said Adolfo Cuevas, assistant professor of social and behavioral sciences at the NYU School of Global Public Health and the study’s lead author. Childhood obesity is a major public health issue in the U.S., affecting nearly one in five children and teens. Black and Hispanic youth experience even higher rates of obesity, which research shows may stem from factors such as poverty, neighborhood access to healthy foods, and single-parent households. ...
- Source: drugdu
- 109
- July 14, 2023
Clinical Trial Set to Change Kidney Transplant Practice

A major clinical trial has found a simple change to world practice for kidney transplants could deliver real benefits for recipients and reduce their need for dialysis by 25%. The BEST-Fluids trial was conducted by the Australasian Kidney Trials Network (AKTN) in collaboration with researchers from The University of Queensland, The University of Adelaide, and The University of Sydney. The research was published in The Lancet. ATKN chair and UQ Professor David Johnson said the trial assessed the use of an intravenous fluid containing sodium, potassium, magnesium and chloride in proportions similar to human blood—instead of the usual practice of using normal saline (sodium chloride and water). “Of those study participants who received intravenous Plasma-Lyte 148, 30% needed dialysis after their transplants, compared to 40% for those given normal saline,” Professor Johnson said. “This is a significant improvement in outcomes for those undergoing kidney transplant surgery.” Royal Adelaide Hospital Nephrologist ...
- Source: drugdu
- 115
- July 14, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.